Rivadem capsules

Rivadem

  • Active Ingredient: Rivastigmine
  • 6 mg, 4.5 mg, 3 mg, 1.5 mg
Buy Now

What is Rivadem?

The active ingredient of Rivadem brand is rivastigmine. Rivastigmine improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical that is important for the processes of memory, thinking, and reasoning. People with dementia usually have lower levels of this chemical. Rivastigmine Tartrate Capsules USP contain Rivastigmine tartrate , equivalent to 1.5 mg, 3 mg, 4.5 mg and 6 mg of Rivastigmine base for oral administration. Inactive ingredients are hypromellose, magnesium stearate, microcrystalline cellulose, and colloidal silicon dioxide. Each hard-gelatin capsule contains gelatin, titanium dioxide and red and/or yellow iron oxides.

Used for

Rivadem is used to treat diseases such as: Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease.

Side Effect

Possible side effects of Rivadem include: Bloody or black, tarry stools; constipation; weight loss; loss of appetite; Aggression; trouble urinating.

How to Buy Rivadem capsules online?

To buy Rivadem online - just click on the "Buy Now" button in the top and follow along with our shop. Payment and Order takes a few minutes, and all steps are obvious. We don't take a medical prescription and also we have many procedures of payment. Considering all the details of fast delivery and confidentiality, you can read on the applicable pages on the links in the top menu.

Related Medications

Donecil

Donecil 10mg, 5mg

donepezil

More info

Ledoxan

Ledoxan 50mg

cyclophosphamide

More info

Acasmul

Acasmul 180mg, 60mg

diltiazem

More info

Allobeta

Allobeta 300mg

allopurinol

More info

Pill with imprint SANDOZ 620 is Red, Capsule-shape and has been identified as Rivadem Tartrate 4.5 mg. It is supplied by Sandoz Pharmaceuticals Inc..

Rivadem is used in the treatment of parkinson's disease; alzheimer's disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivadem 4.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Rivadem is used to treat the symptoms of dementia, such as memory loss. It is prescribed for people who have dementia which is associated with Alzheimer's disease or Parkinson's disease.

Nervous system

Therapy with Rivadem in patients with mild Alzheimer’s disease induces remodelling of the cholinergic and related neuronal networks in the brain, which is clinically manifested by reduced progression of the disease. Changes in 11 C-nicotine binding have been assessed by dual-tracer PET scanning in 10 patients with mild Alzheimer’s disease ( 127 c ). The main cognitive domain associated with nicotinic receptors after treatment was the attention domain.

Drug administration route

The regional variation in transdermal availability of Rivadem has been explored ( 128 c ). Taking the upper back as the reference site, the relative availability of Rivadem from the other anatomical sites was 100% for the chest, 92% for the upper arm, 80% for the abdomen and 71% for the thigh. From all body sites, Rivadem was detectable in less than an hour after application of the patch.

Generic Name: Rivadem tartrate Dosage Form: capsule

Medically reviewed by Drugs.com. Last updated on Nov 1, 2019.

How Supplied/Storage and Handling

Rivadem Tartrate Capsules USP equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of Rivadem base are available as follows:

1.5 mg – Hard gelatin capsules with orange opaque cap and body printed with WATSON over 3208 on both cap and body in black ink. Carton of 100 capsules (10 capsules each blister pack x 10) NDC 0904-6587-61

Store at 20° to 25°C (68° to 77°F) .

Dispense in a tight, light-resistant container as defined in the USP.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Overdosage

Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug.

As Rivadem has a short plasma half-life of about 1 hour and a moderate duration of acetylcholinesterase inhibition of 8 to 10 hours, it is recommended that in cases of asymptomatic overdoses, no further dose of Rivadem tartrate capsules should be administered for the next 24 hours.

As in any case of overdose, general supportive measures should be utilized.

Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when coadministered with quaternary anticholinergics such as glycopyrrolate. Additional symptoms associated with Rivadem overdose are diarrhea, abdominal pain, dizziness, tremor, headache, somnolence, confusional state, hyperhidrosis, hypertension, hallucinations and malaise. Due to the short half-life of Rivadem, dialysis (hemodialysis, peritoneal dialysis, or hemofiltration) would not be clinically indicated in the event of an overdose.

In overdoses accompanied by severe nausea and vomiting, the use of antiemetics should be considered. A fatal outcome has been rarely reported with Rivadem.

Info about where to order Oxat tablets for treatment Postpartum Depression

Cholinesterase inhibitors, including Rivadem, may be expected to increase gastric acid secretion due to increased cholinergic activity. Monitor patients using EXELON for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of Rivadem have shown no significant increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Alzheimer’s Disease

Rivadem tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD).

Rivadem is primarily metabolized through hydrolysis by esterases. Minimal metabolism occurs via the major cytochrome P450 isoenzymes. Based on in vitro studies, no pharmacokinetic drug interactions with drugs metabolized by the following isoenzyme systems are expected: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19, or CYP2B6.

No pharmacokinetic interaction was observed between Rivadem taken orally and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. The increase in prothrombin time induced by warfarin is not affected by administration of Rivadem.

Rivadem (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson’s disease.

OVERDOSE

Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug.

As Rivadem has a short plasma half-life of about 1 hour and a moderate duration of acetylcholinesterase inhibition of 8 to 10 hours, it is recommended that in cases of asymptomatic overdoses, no further dose of EXELON should be administered for the next 24 hours.

As in any case of overdose, general supportive measures should be utilized.

Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when coadministered with quaternary anticholinergics such as glycopyrrolate. Additional symptoms associated with Rivadem overdose are diarrhea, abdominal pain, dizziness, tremor, headache, somnolence, confusional state, hyperhidrosis, hypertension, hallucinations and malaise. Due to the short half-life of Rivadem, dialysis (hemodialysis, peritoneal dialysis, or hemofiltration) would not be clinically indicated in the event of an overdose.

In overdoses accompanied by severe nausea and vomiting, the use of antiemetics should be considered. A fatal outcome has been rarely reported with Rivadem.

EXELON (Rivadem tartrate) Capsules equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of Rivadem base are available as follows:

1.5 mg capsule - yellow, “Exelon 1,5 mg” is printed in red on the body of the capsule.

Bottles of 60 - NDC 0078-0323-44 Bottles of 500 - NDC 0078-0323-08 Unit Dose (blister pack) Box of 100 (strips of 10) - NDC 0078-0323-06

3 mg capsule - orange, “Exelon 3 mg” is printed in red on the body of the capsule.

Bottles of 60 - NDC 0078-0324-44 Bottles of 500 - NDC 0078-0324-08 Unit Dose (blister pack) Box of 100 (strips of 10) - NDC 0078-0324-06

4.5 mg capsule - red, “Exelon 4,5 mg” is printed in white on the body of the capsule.

Bottles of 60 - NDC 0078-0325-44 Bottles of 500 - NDC 0078-0325-08 Unit Dose (blister pack) Box of 100 (strips of 10) - NDC 0078-0325-06

6 mg capsule - orange and red, “Exelon 6 mg” is printed in red on the body of the capsule.

Bottles of 60 - NDC 0078-0326-44 Bottles of 500 - NDC 0078-0326-08 Unit Dose (blister pack) Box of 100 (strips of 10) - NDC 0078-0326-06

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F-86°F) . Store in a tight container.

Cholinomimetic and Anticholinergic Medications

Rivadem may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine). Concomitant use of Rivadem with medications having these pharmacologic effects is not recommended unless deemed clinically necessary .

Parkinson’s Disease Dementia

Rivadem tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD).


© Copyright 2017-2020 - rootsdentclinic.com - We Care About You!

Sitemap